[go: up one dir, main page]

DK2634194T3 - Anti-cdh3-antistof med høj internaliseringskapacitet - Google Patents

Anti-cdh3-antistof med høj internaliseringskapacitet Download PDF

Info

Publication number
DK2634194T3
DK2634194T3 DK11836461.1T DK11836461T DK2634194T3 DK 2634194 T3 DK2634194 T3 DK 2634194T3 DK 11836461 T DK11836461 T DK 11836461T DK 2634194 T3 DK2634194 T3 DK 2634194T3
Authority
DK
Denmark
Prior art keywords
antibody
asp
leu
val
thr
Prior art date
Application number
DK11836461.1T
Other languages
English (en)
Inventor
Keisuke Ishii
Keiko Katsumi
Tadashi Matsuura
Yukio Sudo
Katsuyuki Mitomo
Katsushi Kouda
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Application granted granted Critical
Publication of DK2634194T3 publication Critical patent/DK2634194T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

1. Anti-p-cadherin IgG monoklonalt antistof, hvor antistoffet er fremstillet af et hybridom deponeret under accessionsnummer NITE BP-988, eller NITE BP-1145, eller hvor antistoffet er fremstillet afen celle deponeret under accessionsnummer NITE BP-1147, eller NITE BP-1148.
2. Antistoffet ifølge krav 1, hvor det monoklonale antistof er et kimært antistof, eller humaniseret antistof.
3. Cytotoksisk middel, som omfatter antistoffet ifølge et hvilket som helst af kravene 1 til 2.
4. Det cytotoksiske middel ifølge krav 3, hvor et cytotoksisk stof er konjugeret til antistoffet, hvor det cytotoksiske stof er et maytansinoid-derivat valgt fra DMI, DM3 eller DM4 eller et auristatin-derivat valgt fra MMAE eller MMAF.
5. Det cytotoksiske middel ifølge kravene 3 til 4, hvor antistoffet er konjugeret til et cytotoksisk stof via en linker.
6. Det cytotoksiske middel ifølge krav 5, hvor linkeren er valgt fra gruppen bestående af: sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexan-l-carboxylat (Sulfo-SMCC), N-succinimidyl-4-(maleimidomethyl)cyclohexancarboxylat (SMCC), N-succinimidyl-4-(N-maleimidomethyl)-cyclohexan-l-carboxy-(6-amidocaproat) (LC-SMCC), rc-maleimidoundecansyre N-succinimidylester (KMUA), y-maleimidosmørsyre N-succinimidylester (GMBS), ε-maleimidocapronsyre N-hydroxysuccinimidester (EMCS), m-maleimidobenzoyl-N-hydroxysuccinimidester (MBS), N-(a-maleimidoacetoxy)-succinimidester (AMAS), succinimidyl-6-(p-maleimidopropionamido)hexanoat (SMPH), N-succinimidyl-4-(p- maleimidophenyl)-butyrat (SMPB), N-(p-maleimidophenyl)isocyanat (PMPI), 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), p-aminobenzyloxycarbonyl (PAB), N-succinimidyl-4-(2-pyridylthio)pentanoat (SPP), N-succinimidyl (4- iodoacetyl)aminobenzoat (SIAB), valin-citrullin (val-cit), og alanin-phenylalanin (ala-phe).
7. Det cytotoksiske middel ifølge krav 5, hvor antistoffet er konjugeret til DM1 via N-succimmidyl-4-(maleimidomethyl)cyclohexancarboxylat (SMCC).
8. Det cytotoksiske middel ifølge krav 6 eller 7, hvor 1 til 10 DM1 molekyler er konjugeret til et enkelt antistofmolekyle via SMCC.
9. Det cytotoksiske middel ifølge krav 6 eller 7, hvor 3 til 4 DM1 molekyler er konjugeret til et enkelt antistofmolekyle via SMCC.
10. Farmaceutisk sammensætning, der omfatter, som en aktiv ingrediens, det cytotoksiske middel ifølge et hvilket som helst af kravene 3 til 9.
11. Terapeutisk middel til anvendelse i behandling af en sygdom med et højt udtryk af human CDH3, der omfatter, som en aktiv ingrediens, det cytotoksiske middel ifølge et hvilket som helst af kravene 3 til 9.
12. Det terapeutiske middel til anvendelse ifølge krav 11, hvor sygdommen med et højt udtryk af human CDH3 er valgt fra brystkræft, lungekræft, kolonkræft, eller kræft i bugspytkirtlen.
13. Det terapeutiske middel til anvendelse ifølge krav 12, hvor sygdommen er brystkræft.
14. Midlet eller sammensætningen ifølge krav 8 til 10 eller til anvendelsen ifølge kravene 11 til 13, hvor nævnte antistof konjugeret til DM1 via SMCC udviser en cellevækstinhibering ved lpg/ml, hvor en cellevækstinhibering ved lpg/ml er den målte cytotoksisitet af CDH3 udtrykkende celler som er 50 % eller mindre.
DK11836461.1T 2010-10-29 2011-10-28 Anti-cdh3-antistof med høj internaliseringskapacitet DK2634194T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010243708 2010-10-29
JP2011150812 2011-07-07
PCT/JP2011/074958 WO2012057328A1 (ja) 2010-10-29 2011-10-28 高い内在化能力を有する抗ｃｄｈ３抗体

Publications (1)

Publication Number Publication Date
DK2634194T3 true DK2634194T3 (da) 2018-10-01

Family

ID=45994030

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18182161.2T DK3404043T3 (da) 2010-10-29 2011-10-28 Anti-cdh3-antistof med høj internaliseringskapacitet
DK11836461.1T DK2634194T3 (da) 2010-10-29 2011-10-28 Anti-cdh3-antistof med høj internaliseringskapacitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18182161.2T DK3404043T3 (da) 2010-10-29 2011-10-28 Anti-cdh3-antistof med høj internaliseringskapacitet

Country Status (14)

Country Link
US (1) US9328160B2 (da)
EP (3) EP3708586A1 (da)
JP (2) JP6006640B2 (da)
CY (1) CY1121061T1 (da)
DK (2) DK3404043T3 (da)
ES (2) ES2931477T3 (da)
HR (1) HRP20181438T1 (da)
HU (1) HUE039375T2 (da)
LT (1) LT2634194T (da)
PL (2) PL2634194T3 (da)
PT (1) PT2634194T (da)
RS (1) RS57646B1 (da)
SI (1) SI2634194T1 (da)
WO (1) WO2012057328A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US20130058947A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
AU2012376421A1 (en) * 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
JP6377601B2 (ja) * 2013-02-15 2018-08-22 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
EP3095462B1 (en) 2014-01-15 2019-08-14 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
AR102649A1 (es) 2014-11-14 2017-03-15 Novartis Ag Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
TN2017000203A1 (en) 2014-11-21 2018-10-19 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
HUE052526T2 (hu) 2014-11-21 2021-05-28 Bristol Myers Squibb Co Antitestek, amelyek tartalmaznak módosított nehéz konstans régiókat
IL294342A (en) * 2020-01-10 2022-08-01 Kling Biotherapeutics B V Epithelial cadherin-specific antibodies
KR20250039373A (ko) 2022-07-15 2025-03-20 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2024108193A2 (en) * 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2345160A1 (en) 2001-04-25 2002-10-25 Roy Fenwick Multifunctional flower pot
CA2445611A1 (en) * 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
EP1446501A2 (en) * 2001-06-25 2004-08-18 Buadbo APS Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
MX2007007011A (es) * 2004-12-09 2007-09-21 Johnson & Johnson Inmunoconjugados anti-integrina, metodos y usos.
EP2444419A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
JP2009528257A (ja) 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法
WO2008146854A1 (ja) * 2007-05-28 2008-12-04 National Institute Of Advanced Industrial Science And Technology 抗モータリン抗体のパラトープ及びエピトープ
JP5593560B2 (ja) 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
WO2010126137A1 (ja) * 2009-05-01 2010-11-04 国立大学法人 東京大学 抗カドヘリン抗体
DK2519542T3 (da) 2009-12-28 2019-01-14 Onco Therapy Science Inc Anti-cdh3-antistoffer og anvendelser deraf.

Also Published As

Publication number Publication date
ES2690469T3 (es) 2018-11-21
PT2634194T (pt) 2018-10-19
EP2634194A4 (en) 2014-05-28
JPWO2012057328A1 (ja) 2014-05-12
PL3404043T3 (pl) 2023-01-02
HUE039375T2 (hu) 2018-12-28
US20130317201A1 (en) 2013-11-28
EP2634194B1 (en) 2018-08-15
PL2634194T3 (pl) 2018-12-31
WO2012057328A1 (ja) 2012-05-03
JP2016175945A (ja) 2016-10-06
EP2634194A1 (en) 2013-09-04
JP6006640B2 (ja) 2016-10-12
SI2634194T1 (sl) 2018-11-30
RS57646B1 (sr) 2018-11-30
EP3404043B1 (en) 2022-10-26
US9328160B2 (en) 2016-05-03
EP3708586A1 (en) 2020-09-16
CY1121061T1 (el) 2019-12-11
EP2634194A9 (en) 2014-04-02
HRP20181438T1 (hr) 2018-11-16
EP3404043A1 (en) 2018-11-21
ES2931477T3 (es) 2022-12-29
LT2634194T (lt) 2018-10-25
DK3404043T3 (da) 2022-11-14

Similar Documents

Publication Publication Date Title
DK2634194T3 (da) Anti-cdh3-antistof med høj internaliseringskapacitet
EP3626825B1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
CN104918958B (zh) 抗ceacam5抗体及其用途
US9764041B2 (en) Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
AU2011215267B2 (en) Radioactive metal-labeled anti-cadherin antibody
TW201138816A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
CA3064697A1 (en) Anti-vtcn1 antibodies and antibody drug conjugates
KR20230124037A (ko) 종양 특이적 claudin 18.2 항체-약물 접합체
EP2957632B1 (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same
WO2012057315A1 (ja) 高い親和性を有する抗cdh3抗体